| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	HC Wainwright & Co. analyst Andrew S. Fein downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers...
 
																	Citigroup analyst Yigal Nochomovitz downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral and lowers the price ...
 
																	
 
																	Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but...
 
																	BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $48 to...
 
																	
 
																	
 
																	Guggenheim analyst Seamus Fernandez downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Buy to Neutral.